MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

Home » J&J loses jury trial in vaginal mesh lawsuit amid federal probe

J&J loses jury trial in vaginal mesh lawsuit amid federal probe

By

women's health illustration

A jury this week sided with a plaintiff in a bellwether product liability lawsuit against Johnson & Johnson (NYSE:JNJ) subsidiary Ethicon’s transvaginal mesh implants.

The news comes on the heels of the healthcare conglomerate’s revelation that it’s under investigation by a 42-state coalition of attorneys general offices regarding marketing of the mesh products.

A New Jersey jury yesterday decided in favor of plaintiff Linda Gross, ruling that J&J and Ethicon failed to properly warn her physicians about the potential risks of transvaginal mesh implantation. Gross claimed the device left her with severe chronic pain that prevents her from working or even sitting.

The jury decided against J&J and Ethicon, finding that the companies didn’t properly disclose the risks of transvaginal mesh implantation and that they misrepresented the products in marketing brochures, Reuters reported.

That’s not the final word on the lawsuit, as far as Ethicon is concerned. The company will present its rebuttal today, Ethicon Surgical Care communications vice president Sheri Woodruff told MassDevice.com.

"We will present evidence to the jury … in the punitive phase of the trial, which followed a mixed verdict by the jury," Woodruff told us. "While we are always concerned when a patient experiences medical conditions like those suffered by the plaintiff, all surgeries for pelvic organ prolapse present risks of complications."

Decisions made in this trial, the 1st of around 1,800 such lawsuits in New Jersey alone, may trickle down to similar cases filed against C.R. Bard (NYSE:BCR), Endo Health (NSDQ:ENDP) and Boston Scientific (NYSE:BSX).

J&J reported in its latest regulatory filing that it is facing about 4,000 plaintiffs with direct claims in pending lawsuits regarding pelvic mesh products.

That includes multi-district litigations filed in the U.S. District Court for Southern West Virginia, as well as class action and personal injury cases in Canada and Australia, according to the J&J filing.

In the same report, J&J revealed that it filed a tolling agreement, effectively extending a statue of limitations, in a federal probe of its surgical mesh marketing. The investigation involves attorneys general offices from 42 states, according to the company.

J&J and Ethicon were unable to comment on the Attorney Generals’ investigations, according to an outside spokesperson.

Johnson & Johnson, the world’s largest medical device operation, isn’t the only device maker under investigation for its transvaginal mesh products. Rival Boston Scientific revealed in November 2012 that the California attorney general’s office had launched a probe of its transvaginal surgical mesh products.

In case you missed it

RSS From Medical Design & Outsourcing

  • FDA’s breakthrough medical device designations tally nears 700
    Stewart Eisenhart, Emergo Group The US Food and Drug Administration has granted almost 700 designations over the past seven years under a voluntary program for expedited regulatory review of medical devices and combination products that facilitate more effective treatment or diagnosis of serious diseases. According to recent metrics published by FDA, the agency has issued a total of… […]
  • Lifecore Biomedical’s owner plans to go all-in on contract development and manufacturing
    Lifecore Biomedical parent company Landec Corp. (Nasdaq:LNDC) plans to take the subsidiary’s name, leadership and headquarters as its own and sell off food businesses to focus on contract development and manufacturing. Santa Maria, California-based Landec said it will rename itself as Lifecore Biomedical “in the near future” and change its Nasdaq ticker to LFCR. Landec… […]
  • COVID-19 immunity test developers at MIT seek diagnostic manufacturer
    MIT researchers have developed a device for predicting an individual’s COVID-19 immunity and are looking for a diagnostic company to get it manufactured in large numbers and approved by the FDA. The lateral flow test uses the same technology as at-home rapid antigen COVID-19 tests to measure neutralizing antibodies for SARS-CoV-2 in a blood sample,… […]
  • GE Healthcare picks AI imaging startups for inaugural Edison Accelerator
    GE Healthcare and Nex Cubed have selected seven companies focused on artificial-intelligence-augmented medical imaging for the first cohort of the Edison Accelerator in Canada. The companies will be matched with mentors and test their technologies with GE’s new Edison Digital Health Platform over the next three months. The program will end with innovation showcase presentations… […]
  • Boston Scientific whistleblower launches corruption investigation
    Boston Scientific (NYSE:BSX) is investigating claims that the company violated the U.S. Foreign Corrupt Practices Act in Vietnam. Marlborough, Massachusetts–based Boston Scientific disclosed receipt of a whistleblower’s allegations in its latest filing with the Securities and Exchange Commission. “In March 2022, the company received a whistleblower letter alleging Foreign Corrupt Practices Act violations in Vietnam.… […]
  • 5 essential leadership lessons from Cathy Burzik for medtech’s next generation of women leaders
    Cathy Burzik, a seasoned senior executive in the healthcare industry, has successfully led major medical device, diagnostic, diagnostic imaging and life sciences businesses. Cathy Burzik, CFB Interests (as told to MedExecWomen co-founder Maria Shepherd) One key to being a successful women leader in MedTech: “Play nice, but play to win.” Cathy Burzik, who received a… […]
  • Stratasys plans to buy Covestro’s additive manufacturing business
    Stratasys (Nasdaq:SSYS) said today that it has a deal to purchase the additive manufacturing materials business of Covestro. The deal includes R&D facilities and activities, global development and sales teams across Europe, the U.S. and China, a portfolio of approximately 60 additive manufacturing materials, and hundreds of patents and patents pending, Stratasys said in a… […]
  • New implant design prevents scar tissue without drugs, MIT says
    Mechanically inflating and deflating an implantable device for 10 minutes a day prevents immune cells from building the scar tissue that has been a major obstacle for artificial pancreas researchers. That’s according to new findings from a team of MIT engineers who built mechanical deflection into a two-chambered, soft polyurethane device tested on mice. By… […]
  • Blue Spark’s TempTraq catches fevers faster. Fever prediction is next.
    Blue Spark Technologies developed the first wireless continuous temperature monitor patch, TempTraq, to enable faster fever detection than standard manual readings every four hours. Westlake, Ohio-based Blue Spark is now looking at fever prediction rather than just detecting them. The R&D team is working on developing an AI neural network model built on the company’s… […]
  • Harvard researchers plan to sell at-home, PCR-grade COVID testing system
    The Harvard University researchers who developed an ultrasensitive, PCR-grade nucleic acid detection technology plan to commercialize it as a portable COVID-19 test. Harvard Medical School professor Peng Yin, who also leads the Wyss Institute for Biologically Inspired Engineering’s Molecular Robotics Initiative, founded 3EO Health to sell the device. “In order to optimize the value of… […]
  • FDA reports sterilization challenge progress as EPA takes aim at EtO emissions
    The FDA offered an update on its efforts to make medical device sterilization safer as the EPA identified 23 U.S. facilities where use of ethylene oxide (EtO) presents a risk to communities. The FDA said it is similarly concerned about unsafe EtO emissions and highlighted work with the medical device industry to reduce EtO usage… […]

Leave a Reply